CNS Pharmaceuticals, Inc. Increase (Decrease) in Other Accounts Payable
CNS Pharmaceuticals, Inc. (CNSP) reported Increase (Decrease) in Other Accounts Payable of -$1.03 million for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayable · last filed 2022-08-12
- CNS Pharmaceuticals, Inc. increase (decrease) in other accounts payable for the quarter ending 2022-06-30 was $1.17K.
- CNS Pharmaceuticals, Inc. increase (decrease) in other accounts payable for the quarter ending 2022-03-31 was -$1.03M, a 1027.77% decline year-over-year.
- CNS Pharmaceuticals, Inc. increase (decrease) in other accounts payable for the quarter ending 2021-12-31 was $61.25K, a 91.20% decline year-over-year.
- CNS Pharmaceuticals, Inc. increase (decrease) in other accounts payable for the quarter ending 2021-09-30 was $569.08K, a 470.98% increase year-over-year.
- CNS Pharmaceuticals, Inc. increase (decrease) in other accounts payable for fiscal 2021 was $576.49K, a 17.96% decline from fiscal 2020.
- CNS Pharmaceuticals, Inc. increase (decrease) in other accounts payable for fiscal 2020 was $702.66K.
| Period end | Increase (Decrease) in Other Accounts Payable 3 month | Increase (Decrease) in Other Accounts Payable 6 month | Increase (Decrease) in Other Accounts Payable 9 month | Increase (Decrease) in Other Accounts Payable 12 month |
|---|---|---|---|---|
| 2022-06-30 | $1.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$1.03M 10-Q · filed 2022-08-12 | -$970.69K derived: sum of 3 quarters · filed 2022-08-12 | -$401.61K derived: sum of 4 quarters · filed 2022-08-12 |
| 2022-03-31 | -$1.03M 10-Q · filed 2022-05-13 | -$971.86K derived: sum of 2 quarters · filed 2022-05-13 | -$402.78K derived: sum of 3 quarters · filed 2022-05-13 | -$567.97K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-12-31 | $61.25K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $630.33K derived: sum of 2 quarters · filed 2022-03-03 | $465.14K derived: sum of 3 quarters · filed 2022-08-12 | $576.49K 10-K · filed 2022-03-03 |
| 2021-09-30 | $569.08K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $403.89K derived: sum of 2 quarters · filed 2022-08-12 | $515.24K 10-Q · filed 2021-11-12 | $1.21M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-06-30 | -$165.19K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$53.84K 10-Q · filed 2022-08-12 | $642.31K derived: sum of 3 quarters · filed 2022-08-12 | $741.98K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $111.35K 10-Q · filed 2022-05-13 | $807.50K derived: sum of 2 quarters · filed 2022-05-13 | $907.17K derived: sum of 3 quarters · filed 2022-05-13 | $916.44K derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $696.15K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $795.82K derived: sum of 2 quarters · filed 2022-03-03 | $805.08K derived: sum of 3 quarters · filed 2022-03-03 | $702.66K 10-K · filed 2022-03-03 |
| 2020-09-30 | $99.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $108.93K derived: sum of 2 quarters · filed 2021-11-12 | $6.51K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $9.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | -$93.15K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | -$102.42K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |